Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

4-1-2010

Disruption of the dopamine D2 receptor impairs insulin secretion
and causes glucose intolerance
Isabel García-Tornadú
Consejo Nacional de Investigaciones Científicas y Técnicas

Ana M. Ornstein
Consejo Nacional de Investigaciones Científicas y Técnicas

Astrid Chamson-Reig
Lawson Health Research Institute

Michael B. Wheeler
University of Toronto

David J. Hill
Lawson Health Research Institute

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
García-Tornadú, Isabel; Ornstein, Ana M.; Chamson-Reig, Astrid; Wheeler, Michael B.; Hill, David J.; Arany,
Edith; Rubinstein, Marcelo; and Becu-Villalobos, Damasia, "Disruption of the dopamine D2 receptor
impairs insulin secretion and causes glucose intolerance" (2010). Paediatrics Publications. 678.
https://ir.lib.uwo.ca/paedpub/678

Authors
Isabel García-Tornadú, Ana M. Ornstein, Astrid Chamson-Reig, Michael B. Wheeler, David J. Hill, Edith
Arany, Marcelo Rubinstein, and Damasia Becu-Villalobos

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/678

DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL

Disruption of the Dopamine D2 Receptor Impairs
Insulin Secretion and Causes Glucose Intolerance
Isabel García-Tornadú, Ana M. Ornstein, Astrid Chamson-Reig,
Michael B. Wheeler, David J. Hill, Edith Arany, Marcelo Rubinstein,
and Damasia Becu-Villalobos

The relationship between antidopaminergic drugs and glucose has not been extensively studied,
even though chronic neuroleptic treatment causes hyperinsulinemia in normal subjects or is associated with diabetes in psychiatric patients. We sought to evaluate dopamine D2 receptor (D2R)
participation in pancreatic function. Glucose homeostasis was studied in D2R knockout mice
(Drd2⫺/⫺) mice and in isolated islets from wild-type and Drd2⫺/⫺ mice, using different pharmacological tools. Pancreas immunohistochemistry was performed. Drd2⫺/⫺ male mice exhibited an
impairment of insulin response to glucose and high fasting glucose levels and were glucose intolerant. Glucose intolerance resulted from a blunted insulin secretory response, rather than insulin
resistance, as shown by glucose-stimulated insulin secretion tests (GSIS) in vivo and in vitro and by
a conserved insulin tolerance test in vivo. On the other hand, short-term treatment with cabergoline, a dopamine agonist, resulted in glucose intolerance and decreased insulin response to
glucose in wild-type but not in Drd2⫺/⫺ mice; this effect was partially prevented by haloperidol, a
D2R antagonist. In vitro results indicated that GSIS was impaired in islets from Drd2⫺/⫺ mice and
that only in wild-type islets did dopamine inhibit GSIS, an effect that was blocked by a D2R but not
a D1R antagonist. Finally, immunohistochemistry showed a diminished pancreatic ␤-cell mass in
Drd2⫺/⫺ mice and decreased ␤-cell replication in 2-month-old Drd2⫺/⫺ mice. Pancreatic D2Rs inhibit
glucose-stimulated insulin release. Lack of dopaminergic inhibition throughout development may
exert a gradual deteriorating effect on insulin homeostasis, so that eventually glucose intolerance
develops. (Endocrinology 151: 1441–1450, 2010)

he relationship between dopamine receptors (DR) and
glucose homeostasis has not been extensively studied,
even though some clinical findings suggest a connection.
For example, administration of neuroleptic drugs, which
block DR, causes hyperinsulinemia in normal subjects (1)
or is associated with diabetes in psychiatric patients (2– 4),
and among various adverse reactions of atypical antipsychotics, weight gain and impaired glucose tolerance are

T

clinically significant (5). Furthermore, treatment with the
dopamine precursor L-DOPA in patients with Parkinson’s
disease reduces insulin secretion upon oral glucose tolerance test (6). In rodents, L-DOPA injection results in the
accumulation of dopamine in pancreatic ␤-cells and an
inhibitory action on insulin response to different secretagogues (7, 8), whereas in male rats treated with a dopamine antagonist, high glucose and insulin levels were ob-
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served (9). Insulin secretion is primarily controlled by
metabolism-secretion coupling and is mainly regulated by
glucose, but this process can be modulated by the central
nervous system through parasympathetic and sympathetic
nerves (10).
Dopamine exerts its actions by binding to specific membrane receptors, which belong to the family of seven transmembrane domain G protein-coupled receptors. Five
distinct DR have been isolated, characterized, and subdivided into the D1- and D2-like subfamilies, on the basis
of their biochemical and pharmacological properties (11).
The D1-like subfamily comprises D1R and D5R, whereas
the D2-like includes the D2R, D3R, and D4R. Some in
vitro studies performed in isolated pancreatic islets suggested the participation of the D2R in insulin secretion
(12–14), although the net effect of D2R stimulation observed in these studies and its functional importance remain controversial. In the present study, we sought to
investigate the in vivo role of D2R in insulin secretion and
glucose homeostasis. To this end, we studied ␤-cell function and glucose metabolism in mutant mice lacking D2R
in comparison with their wild-type siblings. A battery of
selective pharmacological tools was used to evaluate the in
vivo and in vitro effects of D2R stimulation and blockade
on insulin secretion and glucose metabolism in both wildtype and D2R-deficient mice (Drd2⫺/⫺). The results presented herein show that even though pancreatic D2R are
inhibitory to glucose-stimulated insulin secretion, permanent loss of D2R causes glucose intolerance.

D2R in pancreatic cells. These Drd2-EGFP mice were originally
generated by the GENSAT (Gene Expression Nervous System
Atlas) project at the Rockefeller University (New York, NY) and
the National Institute of Neurological Disorders and Stroke, National Institutes of Health (Bethesda, MD) (19) and maintained
in an outbred Swiss-Webster genetic background.
All experimental procedures were reviewed and approved
by the institutional animal care and use committee of the Instituto de Biología y Medicina Experimental, Buenos Aires [in
accordance with the Division of Animal Welfare, Office for
Protection from Research Risks, National Institutes of Health,
(A#5072-01)].

Materials and Methods

Reagents
Unless otherwise specified, all chemicals were purchased
from Sigma (St. Louis, MO).

Intraperitoneal glucose tolerance test (IGTT)
IGTT was performed in conscious male Drd2⫺/⫺, wild-type,
and Drd2⫺/⫹ mice at 2 and 7 months of age. Briefly, after overnight fasting (12 h), an ip injection of glucose (2 mg/g body
weight) was administered. Blood glucose levels (2 l obtained
from the tail of each mouse) were examined at 0, 15, 30, and 60
min after glucose injection with a hand-held glucose monitor
(Ascensia Breeze, Bayer, Toronto, Ontario, Canada).
IGTT was also performed in cabergoline-pretreated mice of
both genotypes. To this effect, cabergoline (2 mg/kg ip; Beta
Laboratories, Buenos Aires, Argentina) was administered 1 h
before IGTT (2 mg/g ip glucose). Glucose levels were measured
before glucose administration (time 0) and 30 and 60 min thereafter. Insulin was measured at time 0 and 30 min. A group of
animals was pretreated with haloperidol (3 mg/kg, ip) 30 min
before cabergoline. The difference between pre- and postglucose
levels was calculated as glucose level at 30 or 60 min minus
glucose basal level (time 0). The doses of haloperidol and
cabergoline were selected from our own previous experience
and reports in the literature detailing their effect on DR subtypes (16, 20 –22).

Animals
Male Drd2⫺/⫺ mice, official strain designation B6;129S2Drd2tm1low by the Induced Mutant Resource at The Jackson
Laboratory (Bar Harbor, ME), generated by targeted mutagenesis of the Drd2 gene in embryonic stem cells (15, 16), were used.
The original F2 hybrid strain (129S2/Sv ⫻ C57BL/6J) containing
the mutated Drd allele was backcrossed for at least 10 generations to wild-type C57BL/6J mice. Mutant and wild-type mice
were the product of heterozygote crossings, and in all cases,
control siblings were used. Mice of mixed genotypes were housed
in groups of four or five in a temperature-controlled room with
lights on at 0700 h and lights off at 1900 h and free access to
laboratory chow and tap water. Animals were weighed and used
at 2 and 7 months of age. We chose these two age groups to
determine whether disruption of the D2R had a developmental
effect on glucose homeostasis. Furthermore, prolactin and GH
levels are similar between genotypes at 2 months of age (17),
whereas at 7 months, prolactin levels are markedly increased,
and pituitary GH release is decreased (17, 18).
Transgenic mice carrying an engineered bacterial artificial
chromosome (BAC) in which coding sequences of the enhanced
green fluorescent protein gene (EGFP) are under the transcriptional control of the mouse D2R gene (Drd2) were used to label

Glucose-stimulated insulin secretion (GSIS)
To examine glucose-stimulated insulin secretion, 12-h-fasted
mice were used. Blood was collected from the tail vein before (0
min) and 5, 15, and 30 min after glucose administration (3 mg/g).
Serum samples were immediately obtained by centrifugation at
3000 rpm for 10 min and stored at ⫺20 C. Insulin secretion levels
were assessed by a sensitive rat insulin ELISA kit (Crystal Chem,
Chicago, IL).
GSIS was studied on isolated islets from 7-month-old male
mice of both genotypes. Hand-picked islets were isolated after an
intraductal collagenase V injection, as previously described (23).
Pools of five islets were incubated in 250 l RPMI 1640 medium,
supplemented with 10% fetal bovine serum containing 2.8 mM
glucose for 2 h, and then incubated with 0, 6.25, 12.5, or 25 mM
glucose; 25 mM glucose plus dopamine hydrochloride (10⫺5 or
10⫺8 M) or 25 mM glucose plus dopamine hydrochloride (10⫺5 M)
plus the D2R antagonist (⫺)sulpiride (10⫺5 M Vipral; Laboratorios Roemmers, Buenos Aires, Argentina); or 25 mM glucose
plus dopamine hydrochloride (10⫺5 M) plus the D1R antagonist
SCH 23390 (1-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5
tetrahydro-1H-3-benzazepine (10⫺5 M) for 1 h. Insulin secretion
levels were assessed by RIA. Insulin output was normalized to
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the respective insulin content of the islets. To measure insulin
content, tubes were centrifuged for 10 min at 800 ⫻ g, the
supernatant was discarded, and acid-ethanol was added (250
l/sample; 87.5% vol/vol ethanol plus 12.5% vol/vol 2 N
HCl). Samples were kept overnight at 4 C, centrifuged for 10
min at 800 ⫻ g, and the pellet was discarded. Tris base (85 l,
0.85 M) was added, and samples were stored at ⫺20 C until
measurement.

Intraperitoneal insulin tolerance test (ITT)

RIA
Prolactin was measured by RIA using a kit provided by the
National Institute of Diabetes and Digestive and Kidney Diseases
(Dr. A. F. Parlow, National Hormone and Pituitary Program,
Torrance, CA). Results are expressed in terms of mouse prolactin
standard RP3. Intra- and interassay coefficients of variation were
7.2 and 12.8%, respectively.
For IGF-I RIA, serum samples (15 l) and IGF-I standards
were subjected to the acid-ethanol cryoprecipitation method as
previously described (24). IGF-I was determined using antibody
(UB2-495) provided by Drs. L. Underwood and J. J. Van Wyk
and distributed by the Hormone Distribution Program of the
National Institute of Diabetes and Digestive and Kidney Diseases. Recombinant human IGF-I (Chiron Corp., Emeryville,
CA) was used as radioligand and unlabeled ligand. The assay
sensitivity was 6 pg/tube. Intra- and interassay coefficients of
variation were 8.2 and 14.1%, respectively.
A specific insulin RIA was used as described previously (25)
using human insulin for iodination and standard (Beta Laboratories), and anti-bovine insulin antibody (Sigma). The minimum
detectable concentration was 2 ng, and the intra- and interassay
coefficients of variation were 6.8 and 9.1%, respectively. Pancreatic tissue, 50 mg, was homogenized using a Polytron in 1 ml
ice-cold acidic alcohol (0.18 N HCl/70% ethanol), incubated
overnight at 4 C, and centrifuged at 12,000 rpm for 5 min. The
supernatants were used for determination of insulin concentration by RIA. Results were normalized to the protein content
of samples determined by Qubit Quant it protein assay kit
(Invitrogen, Buenos Aires, Argentina) following manufacturer’s instructions.

Immunohistochemistry
Pancreata from 2- and 7-month-old animals fixed in formalin
were embedded in paraffin, and immunohistochemistry was performed using a modified avidin-biotin peroxidase method as
previously described (26). Antibodies for insulin (polyclonal
guinea pig antiinsulin antibody, 1:200 dilution; Abcam, Cambridge, MA), glucagon (rabbit antiglucagon, 1:200 dilution;
Santa Cruz Biotechnologies, Santa Cruz, CA). Proliferating cell
nuclear antigen (PCNA) (monoclonal mouse anti-PCNA antibody 1:20; Dako, Carpinteria, CA) and EGFP (Abcam, Cambridge, UK) were used. Controls included substitution of primary antiserum with nonimmune serum. Appropriate secondary
antibodies were chosen. Insulin and PCNA immunoreactivity
were visualized using an avidin-biotin kit coupled to alkaline
phosphatase (Vector Laboratories, Burlingame, CA), and glu-
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cagon and EGFP immunoreactivities were visualized using an
avidin-biotin kit coupled to peroxidase (Vector). As chromogens, diaminobenzidine was used for glucagon and EGFP, Vector
Blue AP substrate kit III (SK 5300) for PCNA, and Vector Red AP
substrate kit I (SK 5100) for insulin. Tissue sections were counterstained with hematoxylin.

Morphometric analysis
Morphometric analysis was performed using a Carl Zeiss
transmitted light microscope at a magnification of ⫻250 and
⫻400. Image analysis of pancreatic sections for calculation of
tissue areas was performed by Northern Eclipse, version 6.0 software (Empix, Imaging, Mississauga, Ontario, Canada). The
number of islets (defined as insulin-positive aggregates of at least
20 m diameter) was scored and used to calculate the islet numerical density (number of islets per square centimeter of tissue).
Islets less than 5000 m2 were defined as small, those ranging
from 5000 –10,000 m2 as medium, and those exceeding 10,000
m2 as large. Mean islet size was calculated as the ratio of the
total insulin cell area to the total islet number on the sections. The
␤-cell fraction was determined as the ratio of the insulin-positive
cell area to the total tissue area on the entire section. The ␣-cell
area was calculated by counting glucagon-positive cell area. The
␤-cell mass was obtained by multiplying the ␤-cell fraction by the
pancreas weight. The number of cells that showed nuclear staining for PCNA was related to the total ␤- or ␣-cell area within the
same sections. Data were calculated from three sections of each
pancreas, representing the entire pancreas for each animal (head,
body, and tail). Approximately 70 –120 islets per section were
analyzed. Four animals were studied per genotype and age, unless otherwise stated in the figure legends.

Statistical analysis
Plasma glucose, insulin, prolactin, and IGF-I titers and all
morphometric data are expressed as means ⫾ SEM. The differences between means were analyzed by the unpaired Student’s t
test (in the case of only two groups) or by two-way ANOVA
followed by Newman-Keuls test or Tukey’s honestly significant
difference test for unequal n. Two-way ANOVA with repeatedmeasures design was used to analyze GSIS (effects of drug and
genotype). P ⬍ 0.05 was considered significant.

Results
Body weight was decreased in 7-month-old Drd2⫺/⫺ male
mice compared with their normal wild-type littermates
(23.4 ⫾ 0.08 vs. 27.1 ⫾ 0.5 g, P ⫽ 0.045). Serum prolactin
levels were significantly increased in Drd2⫺/⫺ vs. wildtype mice (154.1 ⫾ 29.1 vs. 6.0 ⫾ 0.2 ng/ml, P ⫽ 0.023),
and even though there were no significant differences in
circulating levels of GH, IGF-I concentration was lower in
Drd2⫺/⫺ mice (815 ⫾ 61 vs. 1325 ⫾ 89 ng/ml, P ⫽ 0.035).
Glucose and insulin responses to glucose overload
in vivo in Drd2ⴚ/ⴚ mice and wild-type littermates
We investigated the impact of the lack of D2R on glucose homeostasis in vivo in male mice. Fasting glucose
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FIG. 1. A and B, Glucose and insulin response in vivo. IGTT (2 mg/g) in
mice of both genotypes (WT, wild-type) at 2 (A) and 7 (B) months of
age. n ⫽ 5– 8 for each group. Two-way ANOVA with repeatedmeasures design: *, P ⬍ 0.05 vs. time-matched Drd2⫺/⫺ mice. C and
D, Insulin secretion in response to glucose (3 mg/g) in mice of both
genotypes at 2 (C) and 7 (D) months of age. n ⫽ 4 and 4 (C) and 11
and 13 (D) for wild-type and Drd2⫺/⫺ mice. *, P ⬍ 0.05 vs. timematched Drd2⫺/⫺ mice.

levels in 7-month-old Drd2⫺/⫺ mice were significantly
higher than in wild-type mice (127 ⫾ 6 vs. 105 ⫾ 6 mg/dl,
P ⫽ 0.040; n ⫽ 12 and 13, respectively), whereas no significant differences were found in fasting insulin levels
(0.07 ⫾ 0.02 vs. 0.12 ⫾ 0.04 ng/ml, P ⫽ 0.36; n ⫽ 15 and
14). In 2-month-old Drd2⫺/⫺ mice, glucose response to
IGTT was similar to that observed in wild-type mice (Fig.
1A). However, 7-month-old Drd2⫺/⫺ mice showed relative glucose intolerance; blood glucose levels were significantly higher than those observed in wild-type littermates
15, 30, and 60 min after the ip glucose load (Fig. 1B, P ⫽
0.0012). On the other hand, basal glucose levels and IGTT
in 7-month-old heterozygotes (Drd2⫺/⫹) were similar to

those of wild-type mice (Supplemental Fig. 1, published on
The Endocrine Society’s Journals Online web site at http://
endo.endojournals.org), and therefore, the rest of the experiments were performed using only Drd2⫺/⫺ and wildtype mice.
To examine the insulin secretory response to glucose in
vivo, 2- and 7-month-old mice of both genotypes were
used after a 12-h fasting period. Serum insulin concentrations were measured before (time 0) and 5, 15, and 30 min
after glucose injection (3 mg/g, ip). In wild-type 2-monthold mice plasma insulin concentrations rose 1.75-fold at
15 min, whereas no increase was observed in Drd2⫺/⫺
mice (Fig. 1C; P ⫽ 0.028, Drd2⫺/⫺ vs. wild-type at 15
min). In 7-month-old wild-type mice, there was a 2.7- and
4.6-fold increase in serum insulin concentration 15 and 30
min after glucose administration, whereas Drd2⫺/⫺ mice
displayed nonsignificant changes in insulin levels at all
times [P ⫽ 0.049 and 0.020, wild-type vs. time-matched
(15 and 30 min) Drd2⫺/⫺ mice; Fig. 1D].
Adult female Drd2⫺/⫺ mice also evidenced glucose intolerance and reduced insulin release evoked by glucose (Supplemental Fig. 2). Nevertheless, because time course of glucose elevation was slightly different and cycling pattern of
ovarian hormones might modify responses in the wild-type
group, we performed the rest of the studies in male mice.

glucose (mg/dl)

Glucose and insulin response to IGTT in vivo in
both genotypes in the presence of dopamine
agonists and antagonists
We next sought to determine whether short-term administration of the D2-like agonist cabergoline could
modify glucose homeostasis in vivo. Cabergoline (2 mg/
kg) did not modify blood glucose levels significantly in
fasted wild-type or Drd2⫺/⫺ mice (not shown). Nevertheless, administration of cabergoline caused relative glucose
intolerance in wild-type mice (Fig. 2A) but not
in Drd2⫺/⫺ mice (Fig. 2B). Blood glucose levels
A
C
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*
*
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wild-type mice (P ⫽ 0.014) but remained eleFIG. 2. IGTT in the presence of cabergoline and haloperidol. A and B, Effect of
⫺/⫺
vated in wild-type cabergoline-treated mice (P ⫽
cabergoline (2 mg/kg) pretreatment on IGTT in wild-type (A) or Drd2
(B) mice.
*, P ⬍ 0.05 vs. respective control; #, P ⬍ 0.05 vs. time-matched cabergoline-treated
0.83, Fig. 2, A and B).
mice. n ⫽ 5 for wild-type mice and 6 for Drd2⫺/⫺ mice. C, IGTT in wild-type
Haloperidol, a dopamine antagonist, parmice in the presence of cabergoline or cabergoline plus haloperidol (3 mg/kg)
tially
blocked glucose intolerance evoked by
(cab⫹hal). *, P ⬍ 0.05 vs. cabergoline-treated mice at 60 min. n ⫽ 4 for each
cabergoline at 60 min in wild-type animals; glugroup. WT, Wild type.
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cose levels decreased at 60 compared with 30 min in wildtype and haloperidol- plus cabergoline-treated and not in
cabergoline-treated mice (P ⫽ 0.0014, 0.0026, and 0.11
for time 60 compared with 30 min in wild-type, haloperidol- plus cabergoline-, and cabergoline-treated mice, respectively; Fig. 2C).

Furthermore, the insulin response observed in wildtype mice after the glucose load (2 mg/g) was attenuated by
cabergoline in wild-type mice (P ⫽ 0.045, Fig. 3A) but not
in Drd2⫺/⫺ mice (Fig. 3B). Pretreatment with 3 mg/kg
haloperidol could not significantly prevent the cabergoline-induced decrease in insulin response (Fig. 3A).
In vitro insulin response to glucose
We next investigated insulin secretion in isolated islets
from 7-month-old male mice of both genotypes. Glucose
(12.5 and 25 mM) increased insulin secretion in islets from
wild-type animals (P ⫽ 0.049 and 0.0011, respectively, vs.
control; Fig. 4A) and not in Drd2⫺/⫺ mice (P interaction
for the effects of dose and genotype ⫽ 0.032). Insulin
release in response to 25 mM glucose was significantly
higher in islets obtained from wild-type compared with
Drd2⫺/⫺ mice (P ⫽ 0.015). Collectively, the in vivo and in
vitro results show that Drd2⫺/⫺ male mice have an impaired insulin response to glucose stimulation.
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FIG. 4. In vitro GSIS. A, GSIS in isolated islets from wild-type (WT) and Drd2⫺/⫺ mice.
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tested the effect of the D2R antagonist
#, P ⬍ 0.05 vs. genotype-matched GLU. E, Effect of pretreatment with 10⫺5 M sulpiride
sulpiride or the D1R antagonist SCH
(DA⫹GLU⫹SUL) or 10⫺5 M SCH23390 (DA⫹GLU⫹SCH) on 10⫺5 M dopamine inhibition
23390 on dopamine inhibition of GSIS
(DA⫹GLU) of glucose-induced insulin secretion in mouse islets from wild-type animals.
*, P ⬍ 0.05 vs. control; n ⫽ 5 experiments performed in triplicate.
in islets obtained from wild-type mice.
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FIG. 3. Insulin response to IGTT and pretreatment with cabergoline.
Insulin response (⌬ insulin) 30 min after a glucose overload of 2 mg/g
in wild-type (A) or Drd2⫺/⫺ (B) mice in the presence or absence of
cabergoline (2 mg/kg), or cabergoline plus haloperidol (3 mg/kg)
(cab⫹hal). *, P ⬍ 0.05 vs. control; n ⫽ 4 for wild-type mice and 5 for
Drd2⫺/⫺ mice. WT, Wild type.
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As shown in Fig. 4E, sulpiride but not SCH 23390 prevented dopamine inhibition, indicating that this effect is
mediated by D2-like receptors (glucose and glucose plus
dopamine plus sulpiride were significantly different from
the control group; P ⫽ 0.0091 and 0.0025, respectively).
Neither dopamine nor sulpiride modified basal glucose
release (not shown).
In vivo insulin action
To assess the effects of D2R deficiency on insulin action
in vivo, we measured the changes in plasma glucose concentrations after a single ip injection of insulin. As shown
in Fig. 5, A and B, glucose disappearance curves were
comparable in both genotypes in 2- and 7-month-old
mice. In 7-month-old mice, glucose was measured up to
120 min to evaluate glucose rebound, and no significant
differences were found. In females, a similar glucose response to ip insulin was found in both genotypes (Supplemental Fig. 2D).
Islet and ␤-cell morphometry in Drd2ⴚ/ⴚ and
wild-type mice and pancreatic insulin content
To further examine the impairment of insulin response
to glucose observed both in vivo and in vitro in Drd2⫺/⫺
mice, we performed a morphometric analysis of the pancreata of 7-month-old male mice of both genotypes. As
shown in Table 1, the ratio of pancreas weight to body
weight was not different between both genotypes, nor was
islet density or average islet size. Islet density and distribution according to size were unaltered between genotypes (Fig. 6A). Percentage of ␤-cell area was not different
between genotypes (Fig. 6B), but a significant decrease in
absolute ␤-cell mass in 7-month-old Drd2⫺/⫺ males compared with wild-type males was observed (Fig. 6C), which
might be related to the tendency to lower pancreas size in
Drd2⫺/⫺ mice (Table 1). Furthermore, there was a decrease in pancreatic insulin concentration (nanograms per
microgram protein) measured by RIA (Table 1). In con-
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FIG. 6. Immunohistochemistry. A, Percentage of large (⬎10,000
m2), small (⬍5,000 m2), and medium (5,000 –10,000 m2) islets in
pancreas from 7-month-old wild-type (WT) and Drd2⫺/⫺ mice; B,
percentage of insulin immunoreactive area (␤ area) in relation to total
pancreatic area of the section; C, ␤-cell mass (obtained by multiplying
the ␤-cell fraction by the pancreas weight). Three different pancreas
sections from each animal (n ⫽ 6 animals per genotype) were
immunostained for insulin and glucagon and subjected to
morphometric analysis. *, P ⬍ 0.05 vs. wild type.

trast, we did not detect changes in ␣-cell mass or insulin to
glucagon ratio between genotypes (Table 1).
Pancreatic ␤-cell proliferation
The preceding results suggested that the absence of
D2R might be responsible for reduced ␤-cell mass and
impaired insulin response to glucose, accounting for the
subsequent impairment in glucose tolerance. To determine whether D2R might participate in the proliferation
of ␤-cells within the islet, we examined costaining of
PCNA with insulin or glucagon in pancreatic cell sections
obtained from mice of both genotypes at 2 and 7 months
of age. As shown in Fig. 7B, insulin cells undergoing replication, measured by PCNA-positive nuclei per given
␤-cell area, exhibited a 54% reduction in pancreas from
2-month-old Drd2⫺/⫺ mice when compared with those of
the wild-type pancreas, suggesting a decrease in ␤-cell proliferative capacity at this early stage. By 7 months, this
decrease in ␤-cell proliferation was not evident (Fig. 7C).
No differences in PCNA-positive cells per ␣-cell area were
observed (not shown). Because at 2 months of age there
was already a developmental effect related to the lack of
D2R, we included immunohistochemistry data of a
younger group (less than 1 month old) and could demonstrate that proliferation of ␤-cells (measured by the percentage of PCNA-stained nuclei in ␤-cells) was impaired
already at 1 month (Fig. 7A).

Discussion
Even though the involvement and importance of dopamine as a neurotransmitter and neuromodulator in the
regulation central nervous system function are well
known, the effects of dopamine on insulin secretion and
pancreatic ␤-cell function are poorly understood. The par-

Downloaded from https://academic.oup.com/endo/article/151/4/1441/2456633 by guest on 08 August 2022

FIG. 5. ITT in fasted male mice of both genotypes at 2 (A) and 7 (B)
months of age. Males were injected with 1 U/kg body weight human
insulin, and blood glucose was measured at different times; n ⫽ 14
(WT) and 15 (Drd2⫺/⫺) for 2-month-old and 18 and 20 for 7-monthold mice.
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TABLE 1. Effects of D2R deficiency on islet density,
size, ␣-cell fraction and mass, insulin to glucagon ratio,
and pancreatic insulin concentration in 7-month-old
mice
WT

Drd2ⴚ/ⴚ

0.075
0.12
0.76
0.38
0.26
0.54
0.017

For the first six parameters, n ⫽ 6 and 7; for insulin concentration
measured by RIA, n ⫽ 7 and 5.

ticipation of the D2R on pancreatic function has been
mainly studied using pharmacological agents with limited
selectivity in vivo, or in vitro studies that preclude an integrative physiological analysis. To address the problem
more directly, we combined the use of mice carrying targeted deletion of the D2R gene and different pharmacological agonists and antagonists, in vivo and in vitro. We
report that the D2R play a crucial role in insulin secretion
and glucose homeostasis; Drd2⫺/⫺ male mice exhibit an
impairment of insulin response to glucose overload and
high fasting blood glucose levels, are glucose intolerant,
and possess a reduced ␤-cell mass at 7 months of age.
Decreased glucose tolerance was observed in Drd2⫺/⫺
mice of both sexes, but we performed most experiments in
male mice because cycling sexual hormones in females
might influence glucose homeostasis (27, 28).
The reduction in ␤-cell mass, decreased insulin concentration, and a defect in glucose-sensing or stimulus-secretion coupling in the ␤-cells in D2R-deficient mice might
explain the supra-normal rise in blood glucose levels that
is evidenced after a glucose challenge. In turn, this reduction in pancreatic ␤-cell mass may be due to a decreased
replication in earlier ages, as shown by the reduction in
PCNA-positive ␤-cells in 1- and 2-month-old Drd2⫺/⫺
mice. On the other hand, results of the glucose and insulin
tolerance tests suggest that glucose intolerance is mainly
caused by a blunted insulin secretory response rather than
an increase in peripheral insulin resistance. This was confirmed by GSIS in vivo and in vitro. Nevertheless, the
changes in glucose tolerance in Drd2⫺/⫺ mice were modest; fasting blood sugar levels were 21% higher, and
postinjection glucose levels were 22% higher than those in
wild-type mice. Furthermore, Drd2⫺/⫹ mice did not display an intermediate phenotype. In the absence of insulin
resistance, it is likely that severe ␤-cell hypoplasia or dys-

function is required to produce severe glucose intolerance
or overt diabetes.
In wild-type mice, insulin secretion in response to glucose in vivo was blocked by cabergoline pretreatment.
Therefore, to determine the role of pancreatic D2R in the
insulin response to glucose, islets from wild-type and
Drd2⫺/⫺mice were incubated in vitro and subjected to
GSIS in the presence or absence of dopamine. Glucose
stimulated insulin release only in islets obtained from
wild-type mice, and dopamine inhibited this effect. Furthermore, a D2R antagonist but not a D1R antagonist
blocked the inhibitory effect of dopamine on insulin secretion from islets of wild-type mice. These results demonstrate that pancreatic D2R inhibit insulin secretion in
response to glucose.
A basis for the molecular mechanisms mediating dopamine action on glucose-stimulated insulin secretion in
pancreatic ␤-cells has been revealed. DR were described in
INS-1E ␤-cells as well as in dispersed rat, mouse, and human islets (13). In the present study, we confirmed the
presence of D2R in mouse islets using Drd2-EGFP mice. It
has been shown that dopamine exerts a differential effect
on glucose-induced insulin secretion depending on the
concentration used (14). Consequently, some reports documented inhibition (13, 29, 30), whereas others reported
an increase of insulin secretion upon acute dopamine accumulation (30, 31). Because D2R agonists inhibit insulin
secretion at lower concentrations, at higher concentrations, these agonists may act on other receptors or may not
be absolutely specific for a given DR. Our present data
demonstrate that even though pancreatic D2R are inhibitory to glucose-stimulated insulin secretion, permanent
loss of D2R results in decreased insulin response to glucose
in adult mice and that this defect is progressive because
glucose intolerance is not observed in young animals. Our
results also point to an important defect in glucose sensing
or stimulus-secretion coupling in ␤-cells, because there
was a complete lack of responsiveness of islets to glucose
both in vivo and in vitro in 7-month-old mice. A possible
explanation to reconcile results could be that the lack of
D2R-mediated insulin inhibition throughout development in Drd2⫺/⫺ mice exerts a gradual deteriorating effect
on insulin response to glucose, and therefore, at 7 months
of age, islets respond poorly to glucose stimulation, as
occurs in type 2 diabetes. This hypothesis is consistent
with the fact that in diabetes, the prolonged stimulation of
␤-cells depletes insulin granule stores, and eventually,
␤-cells become unable to secrete pulses of insulin and become insensitive to changes in glucose concentration (32).
With regard to the mechanism of action of dopamine,
it has been suggested that a down-regulation of D2R could
influence the regulation of insulin secretion by releasing
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5E-03

1-month-old

B 5E-03

Endocrinology, April 2010, 151(4):1441–1450

2-month-old

C

3.0E-03

7-month-old

2

n PCNA cells/
c
beta are
ea (um )

A

D2R Control of Glucose Metabolism

4E-03

4E-03

3E-03

3E-03

2.5E-03
2 0E-03
2.0E
03

*

2E-03

1.5E-03

*

2E-03

1.0E-03
1E 03
1E-03

1E 03
1E-03

0E+00

0E+00

WT

Drd2-/-

5.0E-04
0.0E+00

WT

Drd2 -/-

WT

Drd2 -/-

epinephrine and norepinephrine from the adrenal medulla, which leads to the inhibition of insulin secretion in
the pancreas (14). On the other hand, it has been reported
that glucose-induced electrical activity of ␤-cells leads
to the opening of voltage-gated calcium channels with
subsequent Ca2⫹ influx and Ca2⫹-dependent exocytosis of insulin (33) and that dopamine decreases cell
membrane depolarization as well as cytosolic Ca2⫹ entry, and thus insulin secretion evoked by glucose stimulation is blunted (13).
On the other hand, variations in circulating hormones
found in Drd2⫺/⫺ mice might participate in altered pancreatic function. To begin with, prolactin levels are
chronically elevated in Drd2⫺/⫺ mice due to the lack of
dopaminergic inhibition at the pituitary level (17). The
physiological significance of prolactin in pancreatic function is mainly indicated by the increased insulin secretion
and islet mass during pregnancy in both rodents and humans (34 –36). Prolactin increases ␤-cell proliferation, insulin gene transcription, and glucose-dependent insulin
secretion in isolated pancreatic islets and rat insulinoma
cells (34 –38). Moreover, in rats with chronic hyperprolactinemia, there is an increase in glucose and insulin concentrations after glucose overload. Men and women with
chronic hyperprolactinemia have postprandial hyperinsulinemia and an exaggerated insulin secretory response to
glucose (39 – 41). In addition, prolactin receptor deficiency is accompanied by islet and ␤-cell hypoplasia, reduced pancreatic insulin, and blunted insulin secretory
response to glucose (42). Therefore, our present results are
not consistent with a main effect of the hyperprolactinemic state on the pancreatic phenotype described, because
hyperprolactinemia per se would evoke the opposite results in ␤-cell mass and insulin secretion to those we describe in the Drd2⫺/⫺ mouse.
On the other hand, GH and serum IGF-I are decreased
in Drd2⫺/⫺ mice. Both hormones promote islet cell proliferation and increase insulin gene transcription and in-

sulin secretion (43– 46). Studies using animal models such
as dwarf rats and GH receptor knockout mice show low
glucose and insulin concentrations concordant with a
state of insulin hypersensitivity (47). In humans, GH-deficient subjects have long been recognized as exhibiting
increased insulin sensitivity, decreased insulin secretion,
and hypoglycemia (48, 49), even though some reports observed insulin resistance in GH-deficient subjects (50, 51).
Therefore, decreased ␤-cell mass and insulin secretion may
be in part related to low GH action found in the Drd2⫺/⫺
mice. Nevertheless, the fact that we did not find increased
peripheral sensitivity to insulin or decreased basal glucose
levels, which are generally present in animal models with
low GH, and our in vitro results highlight the importance
of pancreatic D2R in the phenotype described.
D2R deficiency on other tissues, particularly hypothalamus, may be influencing the phenotype. To this regard,
it has been shown that bromocriptine improves glycemic
control and glucose tolerance in obese type 2 diabetic patients (52) and in nondiabetic obese animals and humans
and that bromocriptine can reverse many of the metabolic
alterations associated with obesity by resetting central (hypothalamic) circadian organization of monoamine neuronal activity. Furthermore, glucose intolerance and insulin
resistance result from decreased dopaminergic input to the
area of the suprachiasmatic nucleus in animal models (53).
Recently, bromocriptine was approved by the U.S. Food
and Drug Administration for the treatment of type 2 diabetes. The drug appears to employ central mechanisms
in ameliorating hyperglycemia. Nevertheless, our study
strongly suggests that pancreatic D2R could also participate in the effect of dopamine agonists. We have recently
studied mice lacking neural D2R (nDrd2⫺/⫺) generated by
us (54) and found that glucose and insulin responses at 30
min after a glucose overload of 3 mg/g were similar to
those of wild-type mice (unpublished results). These results further indicate that the insulin release impairment
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FIG. 7. PCNA-positive ␤-cells. Number of PCNA-positive cells per insulin immunoreactive area (in square micrometers) in pancreatic sections from
mice of both genotypes at 1 (A), 2 (B), and 7 (C) months of age. Three different pancreas sections from each animal (n ⫽ 3 animals) were
immunostained for insulin and PCNA and subjected to morphometric analysis. *, P ⬍ 0.05 vs. age-matched wild type.
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found in the Drd2⫺/⫺ mice was not mainly dependent on
the lack of D2R in the central nervous system.
Our results are relevant in the analysis of some clinical
findings such as the effect of chronic treatment with antipsychotic medications that can induce abnormalities in
glucose metabolism that increase risk for cardiovascular
disease and diabetes (55–57) or the altered glucose tolerance associated with prolonged treatment with atypical
antipsychotics in humans (5) and in animal models (58).
Furthermore, older diabetics who take antipsychotic medications have an increased risk of ending up in the hospital
with elevated blood glucose levels, or hyperglycemia (59).
These data together with our present results clearly demonstrate that D2R are modulators of insulin secretion.
We conclude that mice lacking D2R display an impaired
glucose metabolism and that pancreatic islet D2R are involved in this effect. Our finding that the D2R plays an essential role in ␤-cell proliferation and insulin secretion adds
a novel participant to the list of growth factors and hormones
that control the fundamental and multifactorial process of
glucose homeostasis. It is important to consider that a combination of defects, hormonal and genetic, might aggravate
the metabolic dysfunction that accompanies an isolated signaling defect. Furthermore, this study constitutes a contribution to unraveling glucose intolerance found after prolonged treatments with neuroleptic drugs.
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